From: Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients
Age (years) | 55.5 ± 13.3 |
Female gender (%) | 85 |
Disease duration (years) | 8.4 ± 8.8 |
RF positivity (%) | 76 |
RF absolute level (IU/ml) | 139.3 ± 196.4 |
ACPA positivity (%) | 72 |
CRP level (mg/l) | 17.7 ± 23.8 |
DAS28 score | 5.00 ± 1.59 |
Swollen joint count (n) | 6.56 ± 5.44 |
Current MTX therapy (%) | 64 |
MTX therapy ever (%) | 92 |
MTX non-responder (%) | 51 |
current csDMARD therapy (other than MTX) (%) | 35 |
csDMARD therapy ever (other than MTX) (%) | 76 |
Presence of erosions (%) | 61 |
Current smoker (%) | 26 |
Risk of RRP (%) | 26.8 ± 13.7 |
Risk of RRP ≥ 40% (%) (primary endpoint) | 18,2 |